# Inhalation or nasal corticosteroids and prevalence of hypothalamic-pituitary-adrenal axis suppression in HIV-infected patients

Published: 10-03-2015 Last updated: 21-04-2024

Primary objective:a. How often do inhalation or nasal corticosteroids lead to suppression of the HPA- axis in HIV-treated patients? Secondary objectives:b. Are other variables associated with the HPA-axis suppression? c. Are cortisol measurements in...

Ethical review Approved WMO

**Status** Recruitment stopped **Health condition type** Adrenal gland disorders

Study type Interventional

## **Summary**

#### ID

NL-OMON42012

#### **Source**

ToetsingOnline

#### **Brief title**

incorporate

## **Condition**

Adrenal gland disorders

#### Synonym

adrenal insufficiency

## **Research involving**

Human

## **Sponsors and support**

Primary sponsor: Universitair Medisch Centrum Sint Radboud

1 - Inhalation or nasal corticosteroids and prevalence of hypothalamic-pituitary-adr ... 31-05-2025

**Source(s) of monetary or material Support:** Ministerie van OC&W,AIDS fonds en Radboud UMC afdelingen Apotheek en Toxicologie-farmacologie

### Intervention

**Keyword:** adverse effect, corticosteroid, hypothalamic-pituitary-adrenal axis suppression

## **Outcome measures**

## **Primary outcome**

Proportions of persons with a low morning plasma cortisol or low cortisol after an ACTH stimulation test.

## **Secondary outcome**

b. Proportions of persons with a low morning plasma cortisol or low cortisol after an ACTH stimulation test, stratified e.g. by kind of inhalation corticosteroid, dosage of local corticosteroid and use/no use of CYp3A4 inhibitor.

c. Correlation between cortisol in plasma and hair cortisol.

# **Study description**

### **Background summary**

Case reports describe suppression of the hypothalamic-pituitary-adrenal (HPA) axis caused by local corticosteroids, most often with inhalation corticosteroids. The exact prevalence is not known. Early recognition is important, because suppression of the HPA-axis can lead to significant morbidity and mortality. Suppression of the HPA axis might occur more often when a CYP3A4 inhibitor, e.g. ritonavir, is used next to the local corticosteroid, a combination often used by HIV-patients. Cortisol can be determined in hair. This non-invasive analysis could help in diagnosis of suppressed HPA-axis.

## Study objective

Primary objective:

2 - Inhalation or nasal corticosteroids and prevalence of hypothalamic-pituitary-adr ... 31-05-2025

a. How often do inhalation or nasal corticosteroids lead to suppression of the HPA- axis in HIV-treated patients?

Secondary objectives:

- b. Are other variables associated with the HPA-axis suppression?
- c. Are cortisol measurements in hair as reliable as serum cortisol or an ACTH stimulation test to diagnose suppression of the HPA axis?

## Study design

cross-sectional explorative study

#### Intervention

an ACTH stimulation test, cortisol measurements in blood and hair.

## Study burden and risks

Each person will be screened with a history and a short physical examination. A venous cannula will be inserted for obtaining blood for the plasma cortisol and for the ACTH stimulation test. An ACTH stimulation test has no major complications. A piece of hair is cut for cortisol hair analysis. The risks and burden are minimal, while the future benefits could be great since suppression of the endogenous HPA- axis can be associated with morbidities like hypertension or osteoporosis and can even lead to an adrenal crisis when the local corticosteroid is stopped.

## **Contacts**

#### **Public**

Universitair Medisch Centrum Sint Radboud

geert-grooteplein zuid/10 geert-grooteplein/471 nijmegen 6525ga NL

#### **Scientific**

Universitair Medisch Centrum Sint Radboud

geert-grooteplein zuid/10 geert-grooteplein/471 nijmegen 6525ga NL

## **Trial sites**

## **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

### Age

Adults (18-64 years) Elderly (65 years and older)

## Inclusion criteria

- Receive a treatment for HIV-infection
- > 18 years old
- Current usage of inhalation or nasal corticosteroids
- Willing to give informed consent

## **Exclusion criteria**

- Known adrenal insufficiency
- Concurrent use of topical corticosteroids, usage of oral corticosteroids in the last three months. Intramuscular or intra-articular corticosteroid injections in the last year.
- Contra-indications for tetracosactide: allergy for tetracosactide, Cushings\*s syndrome, refractory heart failure, peptic ulcer, acute psychosis, adrenogenital syndrome
- Pregnant female or breast-feeding female.
- Use of oral contraceptives, since these can heighten the cortisol-binding globulin

## Study design

## **Design**

Study type: Interventional

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

## Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 10-08-2015

Enrollment: 30

Type: Actual

## **Ethics review**

Approved WMO

Date: 10-03-2015

Application type: First submission

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

Approved WMO

Date: 24-02-2016 Application type: Amendment

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

CCMO NL51711.091.14